StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Crinetics Pharmaceuticals — Total revenues by Year

Crinetics Pharmaceuticals — Total revenues ($M) ($M)

Vertex Pharmaceuticals Crinetics Pharmaceuticals — Total revenues: $7.70M in FY2025, up 640.4% from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
7.70
Period ended Dec 31, 2025
Change on a year earlier
+640.4%
1.04 in FY2024
History
8 years
Since FY2018
Sources
5
Documents cited below

Where the FY2025 figure comes from

Source: SEC Filing ↗

Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCrinetics Pharmaceuticals — Total revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 20257.70+640.4%SEC Filing ↗
FY2024Dec 31, 20241.04-74.1%SEC Filing ↗
FY2023Dec 31, 20234.01-15.4%SEC Filing ↗
FY2022Dec 31, 20224.74+338.9%SEC Filing ↗
FY2021Dec 31, 20211.08+1,442.9%SEC Filing ↗
FY2020Dec 31, 20200.07-94.1%SEC Filing ↗
FY2019Dec 31, 20191.19-51.0%SEC Filing ↗
FY2018Dec 31, 20182.43–SEC Filing ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals — Total revenues ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-rev

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.